Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
9.47
+0.20 (2.16%)
At close: Jun 25, 2026, 4:00 PM EDT
9.52
+0.05 (0.53%)
After-hours: Jun 25, 2026, 7:49 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
693.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| Rigel Pharmaceuticals | 299.77M |
| CytomX Therapeutics | 35.54M |
| Aclaris Therapeutics | 8.37M |
| Oculis Holding AG | 1.40M |
CADL News
- 12 hours ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire
- 2 days ago - Candel Therapeutics Transcript: AGM 2026 - Transcripts
- 22 days ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene - TheFly
- 23 days ago - Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire
- 24 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 5 weeks ago - Candel Therapeutics price target raised to $9 from $7 at BofA - TheFly